RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Interleukin 15 in Cell-Based Cancer Immunotherapy.
Interleukin 15 in Cell-Based Cancer Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
基于细胞的癌症免疫疗法,如嵌合抗原受体(CAR)工程化T细胞和自然杀伤(NK)细胞疗法,已成为癌症治疗的一项革命性新支柱。白细胞介素15(IL-15)是一种强效免疫刺激性细胞因子,可增强T和NK细胞免疫应答;其可靠性和效力显示有望提高现有细胞疗法的治疗效果。IL-15在结构上与白细胞介素2(IL-2)相似,可支持CD8+记忆T细胞持续存在,同时抑制IL-2诱导的T细胞死亡,从而更好地维持长期抗肿瘤免疫。本文综述IL-15生物学、IL-15和/或其衍生物作为免疫治疗药物给药的研究,以及过继细胞治疗中经IL-15强化的免疫细胞。还讨论将IL-15纳入细胞免疫治疗的优势和挑战,并提出未来研究方向。
Cell-based cancer immunotherapy, such as chimeric antigen receptor (CAR) engineered T and natural killer (NK) cell therapies, has become a revolutionary new pillar in cancer treatment. Interleukin 15 (IL-15), a potent immunostimulatory cytokine that potentiates T and NK cell immune responses, has demonstrated the reliability and potency to potentially improve the therapeutic efficacy of current cell therapy.
Structurally similar to interleukin 2 (IL-2), IL-15 supports the persistence of CD8 + memory T cells while inhibiting IL-2-induced T cell death that better maintains long-term anti-tumor immunity. In this review, we describe the biology of IL-15, studies on administrating IL-15 and/or its derivatives as immunotherapeutic agents, and IL-15-armored immune cells in adoptive cell therapy.
We also discuss the advantages and challenges of incorporating IL-15 in cell-based immunotherapy and provide directions for future investigation.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。